Pharmacokinetics
Conditions
Keywords
MCT oil
Brief summary
Assessing Ketone levels achieved after varying doses of Medium Chain Triglyceride (MCT) oil
Detailed description
Assessing Ketone levels achieved after varying doses of Medium Chain Triglyceride (MCT) oil in three study populations: \<65 year healthy, 65 and older healthy, and Alzheimer's disease. Each subject attends for 4 study days, receiving incrementally larger MCT doses at each visit for 0g, to 14g, to 28g to 42g.
Interventions
DIETARY_SUPPLEMENTMedium Chain Triglyceride oil
Bulletproof Braine Octane MCT oil
Sponsors
University of Alberta
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* adult, healthy or with AD
Exclusion criteria
* unable to attend all study days * coconut allergy * Diabetes
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum plasma concentration (Cmax) | 3 months | Calculation of Cmax to varying doses in each subject and in different study arms. |
| Time to maximum plasma concentration (tmax) | 3 months | Calculation of tmax to varying doses in each subject and in different study arms. |
| Area under the curve (AUC) | 3 months | Calculation of AUC to varying doses in each subject and in different study arms. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| weight | 3months | measured in kg |
| Body fat | 3 months | % measured by bioimpedence scale |
| height | 3 months | measured in cm |
| BMI | 3months | Calculated BMI (ht/m2) |
Countries
Canada
Outcome results
None listed